Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study

@article{Bregante2000FoscarnetPO,
  title={Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study},
  author={Stefania Bregante and S O Bertilson and Elisabetta Tedone and M Teresa van Lint and G. Trespi and Nicola Mordini and Giovanni Berisso and Francesca Gualandi and Teresa Lamparelli and Osvaldo Figari and Federica Benvenuto and A M Raiola and Andrea Bacigalupo},
  journal={Bone Marrow Transplantation},
  year={2000},
  volume={26},
  pages={23-29}
}
This is a dose-finding study using foscarnet for CMV prophylaxis after allogeneic bone marrow transplantation (BMT) in 20 high risk patients (unrelated donors, or T cell depleted, and/or advanced disease). Foscarnet was started on day +1 after BMT and continued until day +100. We explored four different dose levels, patients being entered at the lowest dose level until one patient experiences CMV-reactivation, identified as two consecutive positive CMV antigenemias (CMVAg-emia). The four dose… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Bone Marrow Transplant1997;20: 581–585

  • JD Winston, G Winston, K Bartoni
  • 1997

Bone Marrow Transplant1994;13: 783–788

  • O Ringdén, B Lönnqvist, J Aschan
  • 1994

Similar Papers

Loading similar papers…